BR0309398A - Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase - Google Patents
Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinaseInfo
- Publication number
- BR0309398A BR0309398A BR0309398-0A BR0309398A BR0309398A BR 0309398 A BR0309398 A BR 0309398A BR 0309398 A BR0309398 A BR 0309398A BR 0309398 A BR0309398 A BR 0309398A
- Authority
- BR
- Brazil
- Prior art keywords
- kinase
- treating
- mixtures
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
Abstract
"COMPOSTO OU UM SEU SAL, HIDRATO, SOLVATO, FORMA CRISTALINA, DIASTEREÈMERO, PRODROGA FARMACEUTICAMENTE ACEITáVEL, OU MISTURAS DELES, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA TRATAR UMA CONDIçãO ENVOLVIDA COM A CINASE EM UM MAMìFERO, PARA TRATAR CâNCER, E PARA IDENTIFICAR UMA CINASE". Uma nova composição compreende um composto de Fórmula I seus sais, hidratos, solvatos, formas de cristal, diastereómeros e prodrogas farmaceuticamente aceitáveis ou misturas deles. A composição é de particular utilidade no tratamento de distúrbios implicados com a cinase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37421302P | 2002-04-19 | 2002-04-19 | |
PCT/US2003/012222 WO2003089434A2 (en) | 2002-04-19 | 2003-04-21 | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0309398A true BR0309398A (pt) | 2005-02-01 |
Family
ID=29251159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0309398-0A BR0309398A (pt) | 2002-04-19 | 2003-04-21 | Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase |
Country Status (12)
Country | Link |
---|---|
US (1) | US6919340B2 (pt) |
EP (1) | EP1509526A2 (pt) |
JP (1) | JP2005530739A (pt) |
KR (1) | KR20050008691A (pt) |
CN (1) | CN100537571C (pt) |
AU (1) | AU2003221731B2 (pt) |
BR (1) | BR0309398A (pt) |
CA (1) | CA2482991A1 (pt) |
IL (1) | IL164703A0 (pt) |
MX (1) | MXPA04010288A (pt) |
NO (1) | NO20044974L (pt) |
WO (1) | WO2003089434A2 (pt) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050008691A (ko) | 2002-04-19 | 2005-01-21 | 셀룰러 지노믹스 아이엔씨 | 이미다조[1,2-a]피라진-8-일 아민, 그의 제조방법 및사용방법 |
EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
DE60317353T2 (de) | 2002-09-23 | 2008-08-28 | Schering Corp. | Imidazopyrazine als cdk-inhibitoren |
EP1542693A1 (en) | 2002-09-23 | 2005-06-22 | Shering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005019220A2 (en) * | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
WO2005085252A1 (en) * | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
AU2005251408A1 (en) * | 2004-06-09 | 2005-12-22 | Oncalis Ag | Protein kinase inhibitors |
FR2876582B1 (fr) * | 2004-10-15 | 2007-01-05 | Centre Nat Rech Scient Cnrse | Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
NZ555681A (en) * | 2004-11-10 | 2009-08-28 | Cgi Pharmaceuticals Inc | Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
WO2006076593A1 (en) * | 2005-01-14 | 2006-07-20 | Cgi Pharmaceuticals, Inc. | 1,3-diaryl substituted ureas as modulators of kinase activity |
PL1858877T3 (pl) | 2005-01-14 | 2014-08-29 | Gilead Connecticut Inc | 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy |
US7777040B2 (en) * | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
CN101300015A (zh) * | 2005-11-04 | 2008-11-05 | 默克公司 | 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法 |
US20070117815A1 (en) * | 2005-11-04 | 2007-05-24 | James Pluda | Method of treating cancers with SAHA and pemetrexed |
JP5200939B2 (ja) | 2005-12-23 | 2013-06-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 二環式ヘテロアリール化合物 |
EA200870592A1 (ru) * | 2006-05-31 | 2009-08-28 | Галапагос Н.В. | Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
JP2010509221A (ja) * | 2006-11-03 | 2010-03-25 | ユニバーシテイ・オブ・メリーランド,ボルテイモア | 多発性骨髄腫を治療するためにsahaおよびボルテゾミブを使用する方法 |
US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
NZ587039A (en) | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
JP2012508244A (ja) * | 2008-11-07 | 2012-04-05 | エンゾン ファーマシューティカルズ,インコーポレーテッド | ErbB−3(HER3)選択的併用療法 |
SI2716157T1 (sl) | 2008-12-08 | 2016-10-28 | Gilead Connecticut, Inc., c/o Gilead Sciences, Inc. | Imidazopirazinski Syk-inhibitorji |
ES2744541T3 (es) * | 2008-12-08 | 2020-02-25 | Gilead Connecticut Inc | Inhibidores de imidazopirazina Syk |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
EP2396331B1 (en) * | 2009-02-13 | 2013-10-16 | Bayer Intellectual Property GmbH | Fused pyrimidines as akt inhibitors |
JP5805623B2 (ja) * | 2009-04-16 | 2015-11-04 | フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードFundacion Centro Nacional de Investigaciones Oncologicas Carlos III | キナーゼ阻害剤として使用するためのイミダゾピラジン類 |
RU2607453C2 (ru) * | 2009-12-04 | 2017-01-10 | Сенхва Байосайенсиз, Инк. | Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы |
AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
KR101717809B1 (ko) | 2010-03-11 | 2017-03-17 | 질레드 코네티컷 인코포레이티드 | 이미다조피리딘 syk 억제제 |
CN102939282B (zh) | 2010-04-16 | 2015-12-02 | Ac免疫有限公司 | 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物 |
US20130109683A1 (en) | 2010-06-09 | 2013-05-02 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
JP5834091B2 (ja) | 2010-12-22 | 2015-12-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | ベータ−セクレターゼ(BACE)の阻害剤として有用な5,6−ジヒドロ−イミダゾ[1,2−a]ピラジン−8−イルアミン誘導体 |
MY161407A (en) | 2011-03-01 | 2017-04-14 | Janssen Pharmaceutica Nv | 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
KR102012675B1 (ko) | 2011-03-09 | 2019-08-21 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(BACE)의 억제제로서 유용한 3,4-디하이드로-피롤로[1,2-a]피라진-1-일아민 유도체 |
BR112015030678A8 (pt) | 2013-06-12 | 2020-01-07 | Janssen Pharmaceutica Nv | derivados 4-amino-6-fenil-5,6-di-hidroimidazo [1,5-a] pirazina como inibidores de beta-secretase (bace), composição farmacêutica, processo para preparação da mesma, e usos na fabricação de medicamentos |
MX368326B (es) | 2013-06-12 | 2019-09-27 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace). |
WO2014198854A1 (en) | 2013-06-12 | 2014-12-18 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace) |
TW201601728A (zh) | 2013-07-30 | 2016-01-16 | 吉李德康乃狄克公司 | 脾酪胺酸激酶(SyK)抑制劑之調合物 |
AU2014296308C1 (en) | 2013-07-30 | 2018-09-13 | Kronos Bio, Inc. | Polymorph of Syk inhibitors |
CN103550217B (zh) * | 2013-10-31 | 2014-12-17 | 四川大学 | 一种靶向于细菌rna聚合酶的抗结核小分子化合物 |
MX2016007311A (es) | 2013-12-04 | 2016-09-07 | Gilead Sciences Inc | Metodos para tratar canceres. |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
ES2768823T3 (es) | 2014-12-18 | 2020-06-23 | Janssen Pharmaceutica Nv | Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa |
CN107056789B (zh) * | 2017-04-21 | 2019-03-29 | 陈剑 | 具有取代吡嗪并咪唑类衍生物,其制备及其在医药上的应用 |
CN115028640A (zh) | 2017-08-25 | 2022-09-09 | 吉利德科学公司 | Syk抑制剂的多晶型物 |
EP3927708A1 (en) | 2019-02-22 | 2021-12-29 | Kronos Bio, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2607813B1 (fr) * | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
US5137876A (en) * | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
DE4327027A1 (de) * | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ1,2−aピリジンおよびイミダゾ1,2−aピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
SE9704404D0 (sv) * | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
KR20050008691A (ko) | 2002-04-19 | 2005-01-21 | 셀룰러 지노믹스 아이엔씨 | 이미다조[1,2-a]피라진-8-일 아민, 그의 제조방법 및사용방법 |
WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
EP1542693A1 (en) | 2002-09-23 | 2005-06-22 | Shering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
DE60317353T2 (de) | 2002-09-23 | 2008-08-28 | Schering Corp. | Imidazopyrazine als cdk-inhibitoren |
US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
-
2003
- 2003-04-21 KR KR10-2004-7016841A patent/KR20050008691A/ko not_active Application Discontinuation
- 2003-04-21 CN CNB038144670A patent/CN100537571C/zh not_active Expired - Fee Related
- 2003-04-21 JP JP2003586154A patent/JP2005530739A/ja active Pending
- 2003-04-21 WO PCT/US2003/012222 patent/WO2003089434A2/en active Application Filing
- 2003-04-21 AU AU2003221731A patent/AU2003221731B2/en not_active Ceased
- 2003-04-21 EP EP03718470A patent/EP1509526A2/en not_active Withdrawn
- 2003-04-21 IL IL16470303A patent/IL164703A0/xx unknown
- 2003-04-21 BR BR0309398-0A patent/BR0309398A/pt not_active Application Discontinuation
- 2003-04-21 US US10/419,682 patent/US6919340B2/en not_active Expired - Fee Related
- 2003-04-21 CA CA002482991A patent/CA2482991A1/en not_active Abandoned
- 2003-04-21 MX MXPA04010288A patent/MXPA04010288A/es active IP Right Grant
-
2004
- 2004-11-16 NO NO20044974A patent/NO20044974L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2482991A1 (en) | 2003-10-30 |
IL164703A0 (en) | 2005-12-18 |
KR20050008691A (ko) | 2005-01-21 |
CN1668619A (zh) | 2005-09-14 |
CN100537571C (zh) | 2009-09-09 |
US20030212073A1 (en) | 2003-11-13 |
AU2003221731A1 (en) | 2003-11-03 |
WO2003089434A3 (en) | 2004-01-15 |
AU2003221731B2 (en) | 2010-04-15 |
WO2003089434A2 (en) | 2003-10-30 |
EP1509526A2 (en) | 2005-03-02 |
US6919340B2 (en) | 2005-07-19 |
NO20044974L (no) | 2004-11-16 |
MXPA04010288A (es) | 2005-05-17 |
JP2005530739A (ja) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0309398A (pt) | Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase | |
CR10419A (es) | Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios | |
BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
BRPI0607433A2 (pt) | composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto | |
BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
BRPI0307267B8 (pt) | uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana | |
BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
SE0202462D0 (sv) | Novel use | |
BRPI0612072A2 (pt) | inibidores da aspartil protease | |
ZA200501098B (en) | Novel use of benzothiazole derivatives | |
BRPI0508392A (pt) | materiais e métodos para tratar distúrbios de coagulação | |
YU1899A (sh) | Inhibitori matričnih metaloproteaza na bazi fosfinata | |
AR057295A1 (es) | Combinaciones y procedimientos para usar un compuestos de indolinona | |
BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
BRPI0417345A (pt) | compostos inibidores de quìnase baseados em azola, composições e seus usos | |
BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
TW200806321A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
ATE367390T1 (de) | Phenylalanin enamidderivate | |
DK1557414T3 (da) | IsoquinoIin-forbindelser og medicinsk anvendelse deraf | |
UA98639C2 (en) | Phosphodiesterase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |